Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature

Bibliography

• Lieberman A, Fariello G. Present and future approaches to Parkison disease. Neurology 2006;67:1-4
   Google Scholar
• Parkinson's Disease Foundation [updated 2007; cited 20 May 2007]. Available from: http:www.pdf.org
   Google Scholar
• Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 2006;67:30-8
   Web of Science ®Google Scholar
• Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252:37-42
   Google Scholar
• Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005;22:731-40
   PubMed Web of Science ®Google Scholar
• Schapira A. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1472-8
   PubMed Web of Science ®Google Scholar
• Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-46
   PubMed Web of Science ®Google Scholar
• Reuther M, Spottke EA, Klotsche J, et al. Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007;13:108-14
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;42(20):1484-91
   Google Scholar
• Rascol O, Rascol O, Brooks DJ, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13(1):39-45
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-50
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007 In Print
   Google Scholar
• The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
   PubMed Web of Science ®Google Scholar
• Rascol O, Dubois B, Castro Caldas A, et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN Study. Mov Disord 2006;21:2110-5
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts R, Martin W, et al. Transdermal rotigotine. Arch Neurol 2007;64:676-82
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-mummy, randomized controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson's disease. Neurology 2007;68:1108-15
   PubMed Web of Science ®Google Scholar
• Odin P, Oehlwein C, Storch A, et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand 2006;113:18-24
   PubMedGoogle Scholar
• Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control Study: a 1-year randomized, double-blind trial comparing pirivedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Move Disord 2006;21:500-9
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006;248:266-70
   PubMed Web of Science ®Google Scholar
• Nevan P, Findley LJ, Jeffs JAR, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov Disord 2003;18:1324-31
   PubMedGoogle Scholar
• Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 2006;66:1200-6
   PubMed Web of Science ®Google Scholar
• Grandas F, Hernandez B. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. Eur J Neurol 2007;14:282-9
   PubMedGoogle Scholar
• Pereira da Silva-Junior F, Braga-Neto P, Sueli Monte F, et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005;11:449-52
   PubMedGoogle Scholar
• Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson's disease: a randomized, double-blind study. Neurology 2007;68:45-50
   PubMed Web of Science ®Google Scholar
• Goetz C, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-86
   PubMed Web of Science ®Google Scholar
• Hellman MA, Sabach T, Melamed E, Djaldetti R. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomed Pharmacother 2007;1-3
   PubMedGoogle Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9
   PubMed Web of Science ®Google Scholar
• Noyes K, Hangsheng L, Yue L, et al. Economic burden associated with Parkinson's disease on elderly medicare beneficiaries. Mov Disord 2006;3:362-72
   Web of Science ®Google Scholar
• Tan EK, Yeo AP, Tan V, et al. Prescribing pattern in Parkinson's disease: are cost and efficacy overriding factors? Int J Clin Pract 2005;59:511-4
   PubMedGoogle Scholar
• Vossius C, Gjerstad M, Baas H, et al. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006;113:228-32
   PubMed Web of Science ®Google Scholar
• Schrag A, Banks P. Time loss of employment in Parkinson's disease. Mov Disord 2006;11:1839-43
   Google Scholar
• Korchounov A, Bogomazov G. Employment, medical absenteeism, and disability perception in Parkinson's disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. Mov Disord 2006;21:2220-4
   PubMedGoogle Scholar
• Noyes K, Dick A, Holloway RG, et al. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness. Pharmacoeconomics 2005;12:1257-70
   Google Scholar
• Coyle D, Barbeau M, Guttman M, et al. The economic evaluation of pharmacotherapies for Parkinson's disease. Parkinsonism Relat Disord 2003;9:301-7
   PubMedGoogle Scholar
• Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stavelo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005;21:1005-14
   PubMed Web of Science ®Google Scholar
• Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkison's disease in Finland. Ann Pharmacother 2006;40:651-7
   PubMed Web of Science ®Google Scholar
• Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006;23:693-721
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG, et al. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 2006;1:28-38
   Google Scholar
• Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006;21:616-23
   PubMed Web of Science ®Google Scholar
• Reichmann H, Boas J, MacMahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005;111:21-8
   PubMed Web of Science ®Google Scholar